Exhibit 99.3

CHINA NUVO SOLAR ENERY, INC. AND SUBSIDIARY

(A Development Stage Company)

Pro Forma Consolidated Statement of Operations

For the Nine Months Ended April 30, 2011

2

Notes to the Unaudited Pro Forma Condensed Consolidated Financial Statements

1. Description of the Acquisition and Basis of Presentation

On September 1, 2011, we entered into the First Amendment Share Exchange Agreement with SurgLine, Inc. (“SurgLine”) and the stockholders of SurgLine (the “SurgLine Stockholders”) (the “Share Exchange Agreement”).  Surgline, a Nevada Corporation was formed on March 15, 2011. Pursuant to the Share Exchange Agreement, on September 1, 2011, 17 Stockholders of SurgLine transferred 100% of the outstanding shares of common stock of SurgLine held by them, in exchange for an aggregate of 857,173 shares of Series B Preferred Stock. On September 1, 2011, as a covenant to the Agreement, a majority of the Registrant’s shareholders voted to amend the Registrant’s Articles of Incorporation to increase the number of its authorized shares of capital stock from 1,500,000,000 shares to 6,500,000,000 par value $0.001 shares (the “Amendment”).  Pursuant to the Certificate of Designation of the Series B Preferred Stock and upon the increase in authorized shares of capital stock; the 857,173 shares of Series B Preferred Stock were exchanged for 3,817,554,433 newly issued shares of our Common Stock. Additionally, pursuant to the provisions of the Share Exchange Agreement, the Company issued 163,609,476 newly issued shares of Common Stock to the SurgLine shareholders, in satisfaction of the anti dilution provisions in the Share Exchange Agreement.  The shares of our Common Stock acquired by the SurgLine Stockholders in such transactions constitute approximately 70% of our issued and outstanding Common Stock on a fully-diluted basis giving effect to the share exchange.

On September 1, 2011, we completed the acquisition of SurgLine pursuant to the Share Exchange Agreement. The acquisition was accounted for as a recapitalization effected by a share exchange. SurgLine is considered the acquirer for accounting and financial reporting purposes.  The assets and liabilities of the acquired entity have been brought forward at their book value and no goodwill has been recognized. 

The Acquisition was accounted for as a reverse merger, whereby SurgLine was the continuing entity for financial reporting purposes and was deemed, for accounting purposes, to be the acquirer of China Nuvo. In accordance with the applicable accounting guidance for accounting for a business combination as a reverse merger, SurgLine is deemed to have undergone a recapitalization, whereby it is deemed to have issued equity to China Nuvo’s common equity holders. Accordingly, although the Company, as the parent, legally acquired SurgLine, in accordance with the applicable accounting guidance for accounting for a business combination as a reverse merger, SurgLine’s assets and liabilities will be recorded at their historical carrying amounts, with no goodwill or other intangible assets recorded as a result of the accounting merger of SurgLine with China Nuvo.  The effects of recording the accounting for the reverse merger (which occurred on September 1, 2011) are not reflected in China Nuvo Solar Energy Inc.’s condensed financial statements as of April 30, 2011 but the pro forma effects as of that date are discussed below.

The organizational history of SurgLine is described in SurgLine’s audited financial statements as of June 30, 2011, which are included elsewhere in this Report on Form 8-K.

Basis of Presentation

Certain disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States have been condensed or omitted as permitted by SEC rules and regulations.

These pro forma unaudited condensed consolidated financial statements are not necessarily indicative of the results of operations that would have been achieved had the transaction actually taken place at the dates indicated and do not purport to be indicative of future position or operating results.

The unaudited pro forma condensed consolidated balance sheet was prepared combining the historical balance sheet of SurgLine at June 30, 2011 and the historical balance sheet of China Nuvo at April 30, 2011, as described above.  

The unaudited pro forma condensed consolidated statement of operations includes the historical operations of SurgLine for the period ended June 30, 2011 and the historical operations of China Nuvo.

3

2.  Pro Forma Adjustments and Assumptions

The accompanying unaudited pro forma consolidated financial information gives effect to the Share Exchange as if it had occurred at an earlier date, and has been prepared for illustrative purposes only and is not necessarily indicative of the consolidated financial position or results of operations in future periods or the results that actually would have been realized had SurgLine and China Nuvo been a combined company during the specified periods.  The unaudited pro forma consolidated balance sheet set forth below represents the combined financial position of SurgLine and China Nuvo as of April 30, 2011, as if the reverse acquisition occurred on April 30, 2011.  The unaudited pro forma consolidated statement of operations for the nine months ended April 30, 2011 represents the combined results of operations of SurgLine and China Nuvo, as if the reverse acquisition occurred on the first day of the period presented. Since SurgLine was formed in March 2011, there is not a Pro Forma Consolidated Statement of Operations for the year ended July 31, 2010.

The pro forma adjustments were based on the preliminary information available at the time of the preparation of the unaudited pro forma consolidated financial information. The unaudited pro forma consolidated financial information, including the notes thereto, are qualified in their entirety by reference to, and should be read in conjunction with, the historical consolidated financial statements found as exhibit 99.2 in this Form 8-K.

4